AIM ImmunoTech Inc is trading 85% down at $0.42 after failing to resolve NYSE American equity-deficiency issues by the June 11, 2026, compliance deadline.
- The company faces potential delisting from the NYSE American exchange after missing the deadline to regain compliance with equity standards.
- Investors are reacting to elevated delisting and dilution risks, which have been compounded by the company's recent financing activities.